| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | -0.12 | 0.4 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.4 |
| mRNA | paclitaxel | FIMM | pan-cancer | AAC | -0.11 | 0.4 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.043 | 0.5 |